-- INTERVIEW-Valeant CEO sees revised Allergan bid worth more than $200 per share
-- By Rod Nickel in Winnipeg
-- Mon Oct 20, 2014 10:22AM EDT
-- None



Oct 20 (Reuters) - Valeant Pharmaceuticals Inc <VRX.TO> Chief Executive Michael Pearson said in an interview with Reuters on Monday that he is confident a revised bid for Allergan Inc <AGN.N> will be worth over $200 per share, once Valeant's stock rises and with cash added to the offer.

